GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sumitomo Pharma Co Ltd (OTCPK:DNPUF) » Definitions » Cash, Cash Equivalents, Marketable Securities

Sumitomo Pharma Co (Sumitomo Pharma Co) Cash, Cash Equivalents, Marketable Securities : $297 Mil (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Sumitomo Pharma Co Cash, Cash Equivalents, Marketable Securities?

Sumitomo Pharma Co's quarterly cash, cash equivalents, marketable securities declined from Jun. 2023 ($712.64 Mil) to Sep. 2023 ($462.80 Mil) but then stayed the same from Sep. 2023 ($462.80 Mil) to Dec. 2023 ($297.30 Mil).

Sumitomo Pharma Co's annual cash, cash equivalents, marketable securities declined from Mar. 2021 ($2,053.17 Mil) to Mar. 2022 ($2,012.02 Mil) and declined from Mar. 2022 ($2,012.02 Mil) to Mar. 2023 ($1,224.35 Mil).


Sumitomo Pharma Co Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Sumitomo Pharma Co's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sumitomo Pharma Co Cash, Cash Equivalents, Marketable Securities Chart

Sumitomo Pharma Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,628.93 1,211.37 2,053.17 2,012.02 1,224.35

Sumitomo Pharma Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,136.62 1,224.35 712.64 462.80 297.30

Sumitomo Pharma Co Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Sumitomo Pharma Co  (OTCPK:DNPUF) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Sumitomo Pharma Co Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Sumitomo Pharma Co's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Sumitomo Pharma Co (Sumitomo Pharma Co) Business Description

Industry
Traded in Other Exchanges
Address
6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.